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Abstract
Diabetes mellitus, a disorder of glucose regulation, is a global burden affecting 366 million people
across the world. An artificial “closed-loop” system able to mimic pancreas activity and release
insulin in response to glucose level changes has the potential to improve patient compliance and
health. Herein we develop a glucose-mediated release strategy for the self-regulated delivery of
insulin using an injectable and acid-degradable polymeric network. Formed by electrostatic
interaction between oppositely charged dextran nanoparticles loaded with insulin and glucose-
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specific enzymes, the nanocomposite-based porous architecture can be dissociated and
subsequently release insulin in a hyperglycemic state through the catalytic conversion of glucose
into gluconic acid. In vitro insulin release can be modulated in a pulsatile profile in response to
glucose concentrations. In vivo studies validated that these formulations provided improved
glucose control in type 1 diabetic mice subcutaneously administered with a degradable nano-
network. A single injection of the developed nano-network facilitated stabilization of the blood
glucose levels in the normoglycemic state (<200 mg/dL) for up to 10 days.
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Diabetes mellitus, characterized by accumulating glucose concentrations in the blood, is a
major global public health epidemic which currently affects an estimated 366 million people
across the world.1 Diabetes is a result of the body's inability to produce enough insulin (type
1) or cells that do not respond to the insulin that is produced (type 2). Current standard care
for type 1 diabetic patients and advanced type 2 diabetic patients requires consistent
monitoring of blood glucose levels and subsequent insulin injections to achieve
normoglycemia.2 However, such self-administration, known as open-loop insulin delivery,
can be painful and result in poor compliance and glucose control.3,4 Lack of tight control of
blood glucose levels accounts for many chronic complications of diabetes such as limb
amputation, blindness, and kidney failure, while hypoglycemia results in risks of seizures,
unconsciousness, brain damage, or death.5 In addition, there are challenges to accurate
monitoring of daily glycemic fluctuations in order to intervene with the appropriate insulin
treatments.6,7
Significant effort has been focused on developing a “closed-loop” system capable of
continuously delivering accurate levels of insulin in response to in vivo glucose levels.4,8
One strategy is to integrate both a glucose-sensing moiety and a sensortriggered insulin
releasing element within one system.4 A semiautomated closed-loop insulin delivery device
has been created using a continuous glucose-monitoring sensor and an external insulin
infusion pump. However, challenges, such as guaranteeing accurate signal feedback and
preventing biofouling, associated with this implantable device still persist today.4 An
alternative approach has been to develop polymeric biomaterials to achieve chemically
controlled closed-loop insulin delivery.3,4 Example approaches have been developed by
integration of glucose-sensing moieties such as glucose oxidase (GOx),9–13 lectin
(ConA),14,15 and synthetic phenylboronic acid (PBA).16–20
GOx is an enzyme which catalyzes the conversion of glucose to gluconic acid in the
presence of oxygen shown in the following reaction:21
Previous glucose-responsive systems with GOx typically entrap or immobilize the enzyme
within biomaterials, causing a local decrease in pH with increasing glucose
Gu et al. Page 2






















concentrations.13,22,23 As a result, materials can be designed to adapt to subtle pH changes
which alter the material properties of the device and allow for tailorable release of loaded
insulin in response to increasing blood glucose concentrations. On the basis of this strategy,
a number of bulk hydrogel matrices or membranes have been developed.3,4 However, bulk
hydrogel systems exhibit slow response to changes in glucose concentration due to mass
transport limitations,4 while GOx-containing membranes suffer from low mechanical
strength, which can result in premature insulin leakage.4 In this report, we develop an
injectable polymeric nanoparticle-cross-linked network (designated nano-network) capable
of glucose-mediated insulin delivery. Using chemically modified dextran (designated m-
dextran) as an acid-degradable and biocompatible matrix material, we have demonstrated
that the resulting nano-network can be utilized for glucose-regulated insulin delivery.
RESULTS AND DISCUSSION
A schematic of the nano-network is shown in Figure 1. Oppositely charged degradable
nanoparticles interact and self-assemble through electrostatic forces24 to create a cohesive
gel-like network. The produced gel network forms a stable three-dimensional, porous
structure, which yields an increased surface area to volume ratio for maximum interaction
between glucose and GOx (Figure 2b). Materials of this design have been reported to enable
the release of payloads with near zero-order kinetics.25 Additionally, the nanonetwork
produces shear-thinning behavior due to the disruption of particle–particle interactions as the
applied shear force is increased. Once the external force is withdrawn, the strong cohesive
property is recovered, which allows for convenient molding and injection (Figure 2d).
The nanoparticles used to form this nano-network were prepared by a double emulsion
(water-in-oil-in-water)-based solvent evaporation/extraction method and comprised four
components: acid-degradable polymeric matrix, polyelectrolyte-based surface coatings,
encapsulated glucose-specific enzymes (GOx and catalase (CAT)), and recombinant insulin.
Dextran was selected due to its biocompatibility, biodegradability, and ease of
modification.26 To enable water-soluble dextran to encapsulate hydrophilic payloads,
hydroxyls of dextran were modified with pendant acetals (designated m-dextran) via an
acid-catalyzed reaction with ethoxypropene (Supporting Information Figures S1–S3).27 The
m-dextran is soluble in organic solvents typically used for emulsion techniques, such as
dichloromethane and acetone. More importantly, the incorporation of ethoxypropene
provides a pH-sensitive element, which is expected to hydrolyze under mildly acidic
aqueous conditions and thus unveiling the natural hydroxyl groups of dextran (Supporting
Information Figure S1). The complete hydrolysis of m-dextran results in regeneration of
water-soluble native dextran together with ethanol and acetone, which show insignificant
toxicity in small quantities (Supporting Information Figure S4). The enzyme GOx is the
glucose-responsive factor for generating pH stimulus, while the CAT is applied to offer
oxygen (O2) to assist GOx's catalysis and consume undesired hydrogen peroxide (H2O2)
produced by the reaction (Supporting Information Figure S5), which maybe toxic in vivo
and deactivates GOx.23,28 The weight ratio of GOx to CAT was optimized as 4:1 by
Supporting Information Available: Experimental details for preparation and characterization of the nano-network, in vitro and in vivo
studies. This material is available free of charge via the Internet at http://pubs.acs.org.
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analyzing the catalytic capability of enzyme mixtures at different concentrations (Figure
S5). The final weight ratio of m-dextran/insulin/enzymes for preparation of glucose-
responsive particles was optimized and determined as 87/13/1.3, based on the loading
efficiency of insulin as well as response speed.
In order to obtain oppositely charged nanoparticles, chitosan and alginate, two
polysaccharides that are used in humans,29,30 were employed as surface modifiers to coat
dextran nanoparticles. Both chitosan and alginate were exploited to introduce both a positive
and negative surface charge, respectively, on dextran nanoparticles. Utilizing a double
emulsion procedure, two types of dextran particles were prepared separately with an insulin
loading capacity of 7.9±0.8 wt% for the chitosan-coated particles and 11.4 ± 0.1 wt % for
the alginate-coated particles (Supporting Information Table S1). As shown in the scanning
electron microscopy (SEM) images in Figure 2a, both chitosanand alginate-coated
nanoparticles have nearly monodisperse particle sizes. The average hydrodynamic particle
sizes determined by dynamic light scattering (DLS) for chitosan-coated and alginate-coated
particles were 340 and 293 nm, respectively (Supporting Information Figure S6). The zeta-
potentials for both particles were 10.6±1.9 mV (chitosan-coated) and −11.5± 1.7 mV
(alginate-coated) (Supporting Information Table S2). The uniform and small size of these
nanoparticles provided the cohesive strength, while the opposite zeta-potentials promoted
tight particle packing as a result of the electrostatic interaction.
The cohesive nano-network loaded with both enzymes and insulin (designated NN(E+I))
was created by mixing the oppositely charged dextran nanoparticle solutions. The SEM
image in Figure 2b illustrates that nanoparticles were joined together to form a bulk porous
structure composed of a 3D network with microchannels. The formation of domains
consisting of tightly packed agglomerates suggests that the cohesive nature of the nano-
network resulted from an equilibrium of interparticle attractions (agglomerates) and
repulsions (pores). To further validate the interaction between oppositely charged particles,
insulin conjugated with two different fluorescent dyes was encapsulated into nanoparticles
coated with chitosan and alginate. As demonstrated in Figure 2c, the 3D laser scanning
confocal microscopy (LSCM) indicates that particles in the resulting network were
compacted without noticeable mobility. To investigate the injectability of the nano-network,
the viscosities of each nanoparticle formulation and resulting nanonetwork with the same
solid content were measured as a function of shear rate (Figure 2d). The initial viscosity of
the nano-network at low shear rates compared to pure nanoparticles confirmed the formation
of attractive electrostatic interaction and compact nanoparticle packing. The cohesive forces
were reduced at high shear rate, resulting in the low viscosities that allow for convenient
injection of the nano-network through syringes (Figure 2d).
To examine the glucose-responsive dissociation of the nano-network, gels were collected in
microcentrifuge tubes and incubated with PBS solutions in the absence or presence of
glucose, both at a hyperglycemic level (400 mg dL−1) and a normal level (100 mg dL−1).
The nano-network material exposed to the hyperglycemic solution gradually dissociated
over time, as shown in Figure 3a. After 8 h, the incubated solution became transparent due
to the thorough hydrolysis of the modified dextran into native dextran. Meanwhile, the
recorded pH values of incubating solutions substantiated that the degradation of the network
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correlated to a decrease of the solution pH from 7.4 to 4.2, confirming the enzymatic
conversion of glucose to gluconic acid. In contrast, both of the control samples (no glucose
and 100 mg dL−1 glucose) did not display observable dissociation over the 8 h time course,
consistent with lack of change in the solution pH (Figure 3b). Additionally, we observed that
the viscosity of the nano-network at low shear rates steadily decreased when exposed to
hyperglycemic conditions (Supporting Information Figure S7), as a result of decreasing
cohesive forces due to the changing charges of polyelectrolytes as the pH decreases. The
overall conformational structure of released insulin from the nano-network was maintained
to that of native insulin demonstrated by the circular dichroism (CD) spectrum in Figure 3c.
We next assessed insulin release kinetics in response to varying glucose levels. Accumulated
insulin release studies were performed and confirmed that faster insulin release was
achieved from the nano-networks under a hyperglycemic environment, as plotted in Figure
3d. In contrast, limited insulin release from the nano-networks was observed within 15 h of
incubation at the normal glucose level and glucose-free PBS buffer. These results are also
consistent with the above-mentioned dissociation response. Meanwhile, the solubility of
insulin is increased under an acidic environment, which further enhances the insulin release
rate.22 Furthermore, the insulin release profile of nano-networks presented a pulsatile pattern
when the glucose concentration was cyclically varied between the normal and
hyperglycemic levels every 2 h for several repetitions, as shown in Figure 3e. The
nanonetwork responded to changes of glucose levels, and a maximum 3.6-fold increase in
the insulin release rate was obtained when the glucose level was switched to the
hyperglycemic state. Moreover, the release rates at both hyperglycemic and normoglycemic
levels stably increased to a maximum point and then gradually decreased. The “acceleration
period” of the release rate can be attributed to the progressively attenuated cohesive force
and dissociated structure of the network. Collectively, these results point to the degradation
of the nano-network and the subsequent insulin release is a glucose-mediated and pH-
dependent process. Like a smart valve system, the insulin release through the nano-network
is facilitated at a high glucose level and inhibited at a low glucose level.
To examine the efficacy of the insulin-loaded nanonetwork for diabetes treatment,
streptozotocin (STZ)- induced diabetic mice31 were subcutaneously injected with PBS
solution, human recombinant insulin solution, nano-network loaded with insulin and
enzymes (NN(E+I)), nano-network loaded with insulin only (NN(I)), and nano-network
loaded with enzymes only (NN(E)). The blood glucose (BG) levels of administrated mice in
each group were then monitored over time. As shown in the plots in Figure 4a and Figure S8
(Supporting Information), the BG levels of diabetic mice treated with one injection of NN-
EI were stably maintained in the normoglycemia (<200 mg/dL) range for up to 10 days
without peaks of hyperglycemic or hypoglycemic states. For some of the treated mice, the
BG levels were maintained in the normoglycemic range for over 2 weeks, as shown in
Figure 4b. The average BG levels of the NN(E+I) group gradually increased due to a
decrease in the insulin content or loss of bioactivity of encapsulated insulin but were still
significantly lower than the original BG level for up to 3 weeks. Correspondingly, the
plasma human insulin in mice injected with NN(E+I) can be detected over the 3 week time
course (Figure 4c).
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The rapid decrease in BG levels in the first 12 h (Figure 4a and Figure S8) is likely due to
the initial burst of the insulin released in the solution part or adhered on the surface of the
nano-network. However, the subsequent release of the remaining insulin encapsulated in
nanoparticles, mediated by enzymatic catalysis, took place more slowly (Figure 4a). In
contrast, the BG levels of mice treated with NN(I) maintained BG levels within the normal
range for 2 days before returning to the hyperglycemic state. Meanwhile BG levels of mice
injected with insulin solution increased to the hyperglycemic range on the second day after
administration. In the absence of enzymes, NN(I) cannot undergo an acidic degradation
event to effectively release insulin, and thus the BG levels of administrated mice were
notably higher than those treated with NN(E+I). Without a loading matrix, pure insulin was
quickly cleared and resulted in a rapid decrease in plasma insulin concentration on the next
day of administration (Figure 4a).
To investigate the possible effect of the catalytic consumption of glucose on the decrease of
the BG levels, we also treated diabetic mice with NN(E). However, the conversion of
glucose through enzymes did not show a detectable effect in lowering BG levels (Figure 4a).
The glucose responsiveness was tested in vivo by an intravenous glucose tolerance test at 6
day post-injection (Supporting Information). Mice treated with NN(E+I) showed a rapid
increase in BG levels upon glucose injection followed by a slightly delayed decrease to
finally reach normal BG levels at 80 min in comparison with healthy animals (Supporting
Information Figure S9). We also tested the glycated albumin level in serum, a medium term
(2–3 weeks) indicator of diabetic control.32 As shown in Figure 4d, the glycated albumin
ratio (glycated albumin/total albumin) was prominently decreased 1.6-fold 2 weeks after
administration with NN(E+I). In addition, after a 4 week post-administration period, the
group treated with NN(E+I) gained higher body condition scores compared with control
groups. Taken together, sustained insulin release from the degradable insulin-loaded nano-
network and the pharmacological duration of insulin activity have been observed.
To assess the biocompatibility of the nano-network, the cytotoxicity of nanoparticles coated
with chitosan or alginate and their degradation products toward HeLa cells was evaluated at
various concentrations ranging from 0.05 to 1.2 mg/mL. For all concentrations studied, m-
dextran-based nanoparticles and relevant degradation products did not show significant
decrease of cell viability (Supporting Information Figure S4). To further investigate in vivo
biocompatibility and degradability of the nano-network, the sizes of skin protrusion due to
the subcutaneous injection were monitored over time. As shown in Figure 5a, the average
lump sizes in the injection sites of mice treated with NN(E+I) steadily decreased, suggesting
glucose-mediated degradation was substantially triggered. No significant skin protrusion can
be found after 4 weeks (Figure 5b,c). However, for mice treated with NN(I), the lump sizes
did not obviously decrease, even after 4 weeks. Figure 5d represents the histological
response of the injected nano-network. During the first 2weeks, inflammatory cells, such as
polymorphonuclear cells (PMN) and macrophages, were found to have infiltrated into both
NN(E+I) and NN(I), where the nano-network region was avascular and a cellular, and a
fibrin network separated the nano-network from the muscle region. This inflammatory
reaction can be attributed to the acute inflammation which often occurs when biomaterials
are subcutaneously implanted. After 4 weeks, the NN(E+I) had completely degraded and the
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affected region was covered with connective tissue. However, a noticeable inflammatory
region can still be observed in the samples administrated with NN(I).
CONCLUSION
In conclusion, we report a new platform for glucose-mediated delivery of insulin through an
injectable nano-network. Consisting of oppositely charged dextran nanoparticles
encapsulating insulin and glucose-specific enzymes, the gel-like 3D scaffold can be
effectively dissociated to release insulin in a hyperglycemic condition, where the catalytic
conversion of glucose into gluconic acid and the subsequent degradation of the polymeric
matrix are facilitated. This formulation design provides a potential delivery strategy for both
self-regulated and long-term diabetes management.
METHODS
Materials
All chemicals were purchased from Sigma-Aldrich unless otherwise specified and were used
as received. Human recombinant insulin (Zn salt, 27.5 IU/mg) was purchased from
Invitrogen. The deionized water was prepared by a Millipore NanoPure purification system
(resistivity higher than 18.2 MΩ · cm−1).
Preparation of m-Dextran
Briefly,1.0 g of dextran(Mn~9–11kDa) was added to a flame-dried round-bottom flask and
purged with nitrogen. Ten milliliters of anhydrous dimethyl sulfoxide was added to the flask
and stirred until complete dissolution of the dextran. Pyridinium p-toluenesulfonate (PPTS,
15.6 mg, 0.062 mmol) was added to the solution followed by the addition of 2-
ethoxypropene (4.16 mL, 37 mmol). The reaction mixture was purged with nitrogen briefly
and then sealed with parafilm to prevent reactant evaporation. The reaction was stirred at
room temperature for 30 min, resulting in m-dextran. At that point, the reaction was
quenched by the addition of 1 mL of triethylamine. The mixture was then precipitated and
washed three times in basic water (pH ~8) to prevent undesired degradation and collected by
centrifugation (8000 rpm, 15 min). The product was lyophilized to remove residual water
and resulted in a white solid. IR (KBr, cm−1): 3485, 2971, 2862, 1471, 1374, 1246, 1203,
1047, 806, 746, 549. 1H NMR (400 MHz, CDCl3): δ 5.21 (br, 1H), 4.87 (br, 1H), 4.10–3.70
(br, 12H), 3.46 (br, 4H), 1.30 (br, 16H), 1.11 (br, 8H).
Preparation of Glucose-Responsive Nanoparticles and Nano-Network
Dextran nanoparticles were prepared by an improved double emulsion (water-in-oil-in-
water) solvent evaporation/extraction method. Briefly, 5.8 mL of organic phase
(dichloromethane (DCM)) containing 240 mg of m-dextran was emulsified with 0.5 mL of
aqueous phase containing 35 mg of human recombinant insulin (Invitrogen, USA) only or
together with 3.5 mg of enzymes (weight ratio of glucose oxidase to catalase 4:1) by
sonication for 45 cycles (1 s each with a duty cycle of 60%). Thereafter, the primary
emulsion was immediately poured into 25 mL of the chitosan or alginate aqueous solution
(1%) and sonicated for 45 cycles. The double emulsion was subsequently transferred into
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150 mL of chitosan (Mn = 612 kDa; degree of deacetylation = 96.1%) or alginate (Mv = 1.6
× 105) aqueous solution (0.2%). The mixed suspension was stirred at room temperature to
eliminate DCM by evaporation. After 2 h, the resulting nanoparticles were cleaned and
collected by repeating a procedure of centrifuging at 10 000 rpm and resuspending in
distilled water three times. The product was dried by lyophilization and stored at 4 °C. To
obtain nano-network gels, chitosan- or alginate-coated nanoparticles were separately
dispersed in deionized water (w/v = 20%) and mixed together (w/w = 1/1) in a bath sonitator
for 2 min. The prepared nano-network gel was collected by centrifuging at 3000 rpm for 3
min and stored at 4 °C. The loading capacity (LC) and encapsulation efficiency (EE) of
insulin-encapsulated nanoparticles were determined by measuring the amount of non-
encapsulated insulin through BCA (bicinchoninic acid) protein assay and using insulin-free
particles as basic correction. LC and EE were calculated as LC = (A − B)/C, EE = (A − B)/A,
where A was expected encapsulated amount of insulin, B was the free amount of insulin in
the collection solution, and C was the total weight of the particles.
In Vitro Release Studies
After preparation of the nanonetwork, various solutions (PBS, 100 or 400 mg dL−1 glucose,
500 µL) were added to each tube and incubated at 37 °C on an orbital shaker to evaluate the
release of insulin. At predetermined time points, the sample was centrifuged (8000 rpm, 30
s) and 12 µL of the supernatant was removed for analysis. Twelve microliters of fresh
solution was then added to the tube to maintain a constant volume and placed back within
the incubator. Total insulin content was measured using a Coomassie Plus protein assay. The
absorbance of the well was detected at 595 nm, and the concentration was interpolated from
an insulin standard curve and a calibration curve using the nano-network with enzymes only.
To evaluate the material's ability to adapt to cyclical changes in glucose levels, each
nanonetwork sample was first incubated in 400 mg dL−1 glucose (500 µL) for 2 h at 37 °C.
At that point, the sample was centrifuged (8000 rpm, 30 s) and all of the supernatant was
recovered. The sample was washed twice with PBS and then incubated in 100 mg dL−1
glucose (500 µL) for another 2 h. This cycle was repeated numerous times. Similarly, insulin
concentration was determined using the Coomassie Plus protein assay.
In Vivo Studies Using STZ-Induced Diabetic Mice
The efficacy of the insulin-loaded nano-network for diabetes treatment was evaluated in vivo
by assessment of glycemia in STZ-induced adult diabetic mice (male C57B6, Jackson Lab,
USA). Mice were cared for under supervision of MIT's Division of Comparative Medicine
and in compliance with NIT's Principles of Laboratory Animal Care. The blood glucose
levels of mice were continuously tested for 2 days before administration by collecting blood
(~3 µL) from the tail vein and measuring using the Clarity GL2Plus glucose monitor (VWR,
USA). Eight diabetic mice were selected for each group administered with PBS solution,
insulin solution, nano-network loaded with human recombinant insulin and enzymes, nano-
network loaded with insulin only, or nano-network with enzyme only. One hundred fifty
microliters of the aqueous solution or nano-network was injected using a 1 cc syringe with a
19 gauge needle into the subcutaneous dorsum of mice (insulin dose = 60 mg/kg) that had
been anesthetized with 1% isoflurane. The glucose level of each mouse was monitored over
time (every 30 min or 2 h for the first 12 h in the day of administration and once per day in
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the morning for following days). To measure in vivo insulin concentration, blood samples
(25 µL) were drawn from the tail vein of mice and collected into Sarstedt serum gel
microtubes. Serum samples (5 µL) were stored frozen at −20 °C until assayed. Plasma
insulin concentrations were determined using the human insulin ELISA kit (Calbiotech,
USA). To quantitatively determine ratios of glycated albumin over total albumin
concentration, collected serum samples (7 µL) were analyzed 1 day before administration
and 2 weeks after administration using the mouse glycated albumin kit (Crystal Chem,
USA).
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Schematic of the glucose-responsive nano-network. (a) Nanoparticles (NPs) encapsulating
insulin and glucose-specific enzymes (GOx, glucose oxidase; CAT, catalase) are made of
acidic sensitive acetal-modified dextran (b) and coated with chitosan and alginate,
respectively. (c) Nano-network (NN) is formed by mixing oppositely charged nanoparticles
together and efficiently degrades to release insulin upon the catalytic generation of gluconic
acid under hyperglycemic conditions. (d) Schematic of glucose-mediated insulin delivery for
type 1 diabetes treatment using the STZ-induced diabetic mice model.
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Characterization of the glucose-responsive nano-network. SEM images of nanoparticles
(NPs) coated with chitosan and alginate (a) and formed nano-network (b). Inset is a gel-like
nano-network adhered to the bottom of an inverted vial. (c) Laser scanning confocal
microscopy image of the nano-network consisting of chitosan-coated NPs (encapsulated
with FITC-stained insulin) and alginate-coated nanoparticles (encapsulated with rhodamine-
stained insulin). (d) Viscosity and shear-thinning behaviors of the nano-network compared
with pure nanoparticles. Inset shows that the collected nano-network is injectable with
sufficient cohesiveness through a conventional syringe.
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Glucose-responsive degradation of nano-network and insulin release. (a) Pictures of the
nano-network incubated in different glucose concentrations in 1× PBS solution: 0, 100, and
400 mg/dL at 37 °C over time. (b) Relevant pH changes in different incubation solutions
with nano-networks. (c) CD spectra of insulin solution and insulin released from the
nanonetwork incubated with 400 mg/dL glucose at 37 °C for 8 h. (d) In vitro accumulated
insulin release of the nano-network in different glucose concentrations at 37 °C. (e) Self-
regulated profile of the nano-network presents the rate of insulin release as a function of
glucose concentration. Data points represent mean ± SD (n = 2) in (a), (d), and (e).
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In vivo studies of the nano-network for type 1 diabetes treatment. Blood glucose levels (a)
and plasma human insulin concentration (c) in STZ-induced C57B6 diabetic mice after
subcutaneous injection with 1× PBS, nano-network encapsulated insulin and enzymes
(NN(E+I)), nano-network encapsulated insulin only (NN(I)), nano-network encapsulated
with enzymes only (NN(E)), or pure insulin solution. (b) Changes of the mice number in
different groups within the normoglycemic range (<200 mg/dL) over the administration
time. (d) Glycated albumin percentages of mice treated with PBS, NN(E+I), NN(I), NN(E),
and insulin solution. Student's t-test: *p < 0.05, ***p < 0.001. Data points represent mean ±
SD (n = 8).
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In vivo biocompatibility analysis. (a) Changes of lump sizes in the injection sites of STZ-
induced C57B6 diabetic mice treated with NN(E+I) and NN(I) over time. (b) Pictures of
mice dorsum and relevant skins (c) treated with subcutaneous injection of NN(E+I) or NN(I)
after 4 weeks. Scale bars: 1 cm for (b) and 2mm for (c). (d) H&E stained sections of
subcutaneously injected NN(E+I) or NN(I) with surrounding tissues after 2 and 4 weeks,
respectively. The regions of skin muscles, fat tissues, and nano-networks are indicated by M,
F, and NN, respectively. Scale bar: 200 µm.
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